Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium

Matti A. Vuori1,2*, Jaakko Reinikainen2, Stefan Söderberg3, Ellinor Bergdahl3, Pekka Jousilahti2, Hugh Tunstall-Pedoe4, Tanja Zeller5, Dirk Westermann5, Susana Sans6, Allan Linneberg7,8, Licia Iacoviello9,10, Simona Costanzo8, Veikko Salomaa2, Stefan Blankenberg5, Kari Kuulasmaa2 and Teemu J. Niiranen1,2

Abstract

Background: The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large population-based cohorts with long follow-up times and a wide panel of biologically relevant biomarkers.

Methods: In a population-based sample of 3834 diabetic and 90,177 non-diabetic individuals, proportional hazards models and mediation analysis were used to assess the relation of conventional heart failure risk factors and biomarkers with incident heart failure.

Results: Over a median follow-up of 13.8 years, a total of 652 (17.0%) and 5524 (6.1%) cases of incident heart failure were observed in participants with and without diabetes, respectively. 51.4% were women and the mean age at baseline was 48.7 (standard deviation [SD] 12.5) years. The multivariable-adjusted hazard ratio (HR) for heart failure among diabetic individuals was 2.70 (95% confidence interval, 2.49–2.93) compared to non-diabetic participants. In the multivariable-adjusted Cox models, conventional cardiovascular disease risk factors, such as smoking (diabetes: HR 2.07 [1.59–2.69]; non-diabetes: HR 1.85 [1.68–2.02]), BMI (diabetes: HR 1.30 [1.18–1.42]; non-diabetes: HR 1.40 [1.35–1.47]), baseline myocardial infarction (diabetes: HR 2.06 [1.55–2.75]; non-diabetes: HR 2.86 [2.50–3.28]), and baseline atrial fibrillation (diabetes: HR 1.51 [0.82–2.80]; non-diabetes: HR 2.97 [2.21–4.00]) had the strongest associations with incident heart failure. In addition, biomarkers for cardiac strain (represented by nT-proBNP, diabetes: HR 1.26 [1.19–1.34]; non-diabetes: HR 1.43 [1.39–1.47]), myocardial injury (hs-TnI, diabetes: HR 1.10 [1.04–1.16]; non-diabetes: HR 1.13 [1.10–1.16]), and inflammation (hs-CRP, diabetes: HR 1.13 [1.03–1.24]; non-diabetes: HR 1.29 [1.25–1.34]) were also associated with incident heart failure. In general, all these associations were equally strong in non-diabetic and diabetic individuals. However, the strongest mediators of heart failure in diabetes were the direct effect of diabetes status itself (relative effect share 43.1% [33.9–52.3] and indirect effects (effect share 56.9% [47.7–66.1]) mediated by obesity (BMI, 13.2% [10.3–16.2]), cardiac strain/volume overload (nT-proBNP, 8.4% [-0.7–17.4]), and hyperglycemia (glucose, 12.0% [4.2–19.9]).
Background
Diabetes mellitus is an established heart failure (HF) risk factor. Already in 1974, the Framingham Heart Study investigators observed five- and two-fold increases in HF risk in diabetic women and men compared to their non-diabetic counterparts [1]. In addition, a recent systematic review by Aune et al. that covered over 21 million participants reported a doubled HF risk among diabetic patients [2]. In fact, 45% of patients hospitalized for HF have diabetes [3]. This association between diabetes and HF has been historically considered to be driven by increased coronary atherosclerosis in diabetic individuals. However, in contrast to this assumption, HF risk is also elevated among diabetic individuals without coronary heart disease [4] and in diabetic patients under rigorous glycaemic control [5]. These findings suggest that factors apart from coronary atherosclerosis may contribute to the increased HF risk in diabetes.

Potential non-atherosclerotic cardiometabolic causes for the increased HF risk in diabetes include subclinical inflammation, obesity, alterations in the lipid and energy metabolism, endothelial dysfunction and a cardiac muscle disease seen in diabetes, termed diabetic cardiomyopathy, that is unrelated to hypertension, coronary artery disease, or dyslipidemia [6, 7]. Reduced kidney function and related physiologic alterations may also contribute to the HF risk in patients with diabetes through intravascular volume overload, altered reabsorption or excretion of filtered glucose and/or sodium [8]. In addition, vitamin D levels are often low in individuals with obesity or insulin resistance and are also related to a wide range of cardiovascular and metabolic disorders as well, but ascertaining links to certain disease states, such as HF, have been difficult to make due to the relatively high prevalence of low vitamin D levels [9, 10].

The potential underlying and mediating factors of HF in diabetes are numerous and remain understudied in large well-phenotyped population cohorts with long enough follow-up times needed for HF to develop. We hypothesize that using survival modeling and mediation analyses will help in clarifying the differences between diabetic and non-diabetic individuals in developing HF. This information could help us understand the pathophysiology and the disproportionately increased risk of HF among individuals with diabetes. To reach this goal, both conventional HF risk factors and circulating biomarkers were measured in a large multinational pool of population-based cohorts of 94,011 individuals (55,271 with biomarkers available) with follow-up times up to 28 years totaling 1,326,515 person-years in the whole cohort.

Methods
Study cohorts
The MORGAM (MOnica Risk, Genetics, Archiving and Monograph) project is a multinational collaborative study with harmonized data from population-based cohort studies. The project aims at exploring the relationships between the development of cardiovascular diseases, their classic and genetic risk factors and biomarkers, originating from the WHO MONICA [MutiNational MONItoring of trends and determinants in Cardiovascular disease] projects [11, 12]. Follow-up data for incident hospitalization for HF and its risk factors for up to 29 years (median 14.1 years) are available for 115,868 individuals from 20 cohorts from 6 countries: the FINRISK Study from Finland (baseline data collection carried out every 5 years between 1982–2007 with biomarker assessment in 1997), the Northern Sweden MONICA Study (1986–2009), the DAN-MONICA from Denmark (1982–1992), the Moli-sani Study from Italy (2005–2010), and the Scottish Heart Health Extended Cohort [SHHEC] from the UK (1984–1995).

After pooling these cohorts together, we derived two study samples that were included in the final analyses. Study sample 1 had complete HF follow-up data available (n = 94,011 after exclusions) and study sample 2 had also biomarker data available, being a subsample of the first one (n = 55,271 after exclusions; details in Fig. 1).

Data collection
The diagnostic criteria for baseline disease states varies by cohort and baseline year but is mainly based on International Classification of Diseases (ICD) codes in hospital discharge data for all cohorts [13]. In general, baseline HF was defined with positive replies to survey questions (e.g., “Have you ever been diagnosed with...”, “Has a healthcare professional ever told you you have...”),

Conclusions: The findings suggest that the main mediators of heart failure in diabetes are obesity, hyperglycemia, and cardiac strain/volume overload. Conventional cardiovascular risk factors are strongly related to incident heart failure, but these associations are not stronger in diabetic than in non-diabetic individuals. Active measurement of relevant biomarkers could potentially be used to improve prevention and prediction of heart failure in high-risk diabetic patients.

Keywords: Diabetes, Cardiovascular disease, Heart failure, Mediation, Hazard, Risk, Biomarker
hospital discharge register diagnoses (available in FINRISK, DAN-MONICA, SHHEC and Northern Sweden MONICA studies), or other health care information system (such as linkage with the nationwide Drug Reimbursement Register in FINRISK). Prevalent diabetes was based on self-report and/or register diagnoses (Additional file: Table S1a). Some early surveys did not differentiate between type 1 and type 2 diabetes and for this reason they were analyzed jointly (however, 16% of the diabetic participants were receiving insulin treatment at baseline). Detailed information on data collection, data harmonization, and definition of prevalent and incident disease is available for each cohort online [12].

Biomarker data

Biomarkers used in this study were creatinine, C-reactive protein (hs-CRP), glucose, insulin, HDL cholesterol, LDL cholesterol, triglycerides, C-peptide, n-terminal atrial natriuretic peptide, type B (nT-proBNP), troponin I (hs-TnI), and vitamin D. High sensitivity assays were used for CRP and TnI. All biomarkers were sampled at baseline, deep-frozen and subsequently analyzed in the same central laboratory, except total cholesterol and HDL, which were mainly analyzed locally and during the same day as venous sampling (for Northern Sweden MONICA in 1999–2008, HDL cholesterol was measured from frozen samples in the aforementioned central laboratory). All lipids were serum measurements with > 10 h of fasting in Moli-sani and DAN-MONICA, > 4 h in FINRISK and Northern Sweden MONICA projects, while no fasting was required in SHHEC, which can mainly affect triglycerides levels. Low-density lipoprotein (LDL) cholesterol levels were calculated using the Friedewald formula without any additional hypertriglyceridemia-related adjustments. The laboratory methods and quality control results of the biomarkers have been published earlier [14].

Follow-up

After excluding persons with HF at baseline from the study, the subjects were followed up for their first diagnosis of HF. The follow-up procedures relied on data from national population registers (except in Moli-sani), hospital discharge registers, causes-of-death registers, and death certificates. The follow-up periods started between 1982 and 2005 and ended between 2010 and 2015. Censoring was performed if the subject died from other cause or was lost to follow-up. Cohort-specific diagnostic criteria and follow-up period details with exact ICD codes used for HF and diabetes diagnosis at baseline and follow-up are combined in the Additional file 1: Table S1b and also provided online [12].

Definitions

Smoking was defined as self-reported regular and occasional use of any of the following products: cigarettes, cigarillos, pipes, or cigars. Blood pressure (BP) was measured twice with a manual sphygmomanometer or an...
automated device and the mean of both measurements was used. Height and weight were measured with standard methods to calculate body mass index (BMI). Average alcohol use was calculated as grams per day (g/d) based on self-report.

**Statistical analyses**

As the biomarker data were highly skewed to the right (i.e., a vast majority of cases were in the low or very low end of the range), we performed appropriate transformations (square root for lipid data and cubic root for the rest) and winsorizing (replacing the three highest values with the fourth highest) to avert further skewness caused by extreme outliers. After transformations, missing data were handled using multiple imputation with ten imputed data sets. We used random forests as the imputation method and ensured the convergence of the imputation algorithm and plausibility of imputed values by graphical inspection. After this, the continuous variables were centered by subtracting the variable mean from each variable and scaled by dividing the centered variable values by their standard deviations.

The unadjusted association between diabetes status and incident HF was assessed by estimating cumulative incidence curves for HF in the whole study sample 1 while the association between different risk factors and HF was examined using Cox proportional hazards models in study sample 2. The risk factors consisted of conventional HF risk factors (sex, alcohol use, systolic BP, BMI, smoking, baseline myocardial infarction [MI], and baseline atrial fibrillation [AF]) and several biomarkers (HDL cholesterol, LDL cholesterol, triglycerides, glucose, insulin, nT-proBNP, hs-TnI, creatinine, hs-CRP, and vitamin D). The analyses were performed separately for diabetic and non-diabetic individuals. We fitted models with different levels of adjustment to assess the impact of controlling for other variables. First, all risk factors were analyzed in separate models adjusted for conventional HF risk factors and stratified by cohort. Then, all risk factors were included as predictor variables in the same model and stratified by cohort. In addition, to test whether the association between the risk factor and HF was statistically different in diabetic versus non-diabetic individuals, an interaction term between a risk factor and diabetes status was included, in separate models for each risk factor. It is recommended to use age as time-scale instead of parametric adjustment as a covariate as parametric adjustment assumes that the connection between age and disease is known. In contrast, age as time-scale does not assume this and results in better visualization of the connection [15–17]. For this reason, age was used as the time-scale in all Cox models, resulting in age-adjustment.

An exploratory mediation analysis with selected risk factors as potential mediator variables between diabetes and incident HF was performed in study sample 2. The conceptual model of the mediation analysis and the direct and indirect mediation effects are illustrated in Fig. 2. Baseline diabetes status (established before the baseline measurements) was used as the exposure variable and incident HF (during follow-up time) as the outcome variable, with the baseline biomarkers or conventional risk factors included as potential mediators.

![Conceptual model for mediation analysis](image_url)

**Fig. 2** Conceptual model for mediation analysis. The effect of diabetes mellitus on the incidence of heart failure is divided to direct effect and mediator-driven effect. Covariates associated with the incidence of HF are depicted on the right. An individual’s age is taken into account by using age as the time-scale in the HF-free survival model. HF, heart failure; BP, blood pressure; MI, myocardial infarction; AF, atrial fibrillation; CRP, C-reactive protein; nT-proBNP, n-terminal atrial natriuretic peptide, type B; hs, high-sensitivity assay; TnI, troponin I
of diabetes status on the outcome. We chose to exclude behavioral variables (smoking status and alcohol intake) from the mediation analysis as the effect of diabetes on HF onset cannot be expressed through them. To select the variables to be treated as potential mediators, we followed the approach presented by Yu et al. [18]. For a variable to be considered as a potential mediator, i.e., to be able to convey the predictor’s effect in the outcome, it needed to be significantly associated with both diabetes (exposure) and HF (outcome, with significance level of p < 0.1), when other variables were controlled for. When the aforementioned tests were not passed for a variable, it was used as a covariate by default. After applying these rules, systolic BP, BMI, HDL cholesterol, glucose, triglycerides, creatinine, CRP, nT-proBNP, hs-Tnl, baseline MI, baseline AF, and vitamin D were included as mediator variables whereas sex and cohort were included as covariates.

All analyses were performed using R statistical software, version 3.5.1 [19]. The mediation analysis was performed using the mma-package [20] and multiple imputation using the mice-package [21].

Results
The characteristics of the two study samples are presented in Table 1. In the full study sample (n = 94,011), 51.4% were women and mean age at baseline was 48.7 (standard deviation [SD] 12.5) years. Of this sample, 3834 (4.1%) individuals had baseline diabetes. Of persons with diabetes, 15.8% had insulin treatment, 37% had oral hypoglycemic medication, and 25.8% received only dietary treatment, suggesting that at least over 70% of these participants had type 2 diabetes. Incident HF was more common among diabetic individuals (n = 652; 17.0%) than among non-diabetic individuals (n = 5524; 6.1%) over a median follow-up time of 13.8 (interquartile range 5.7–22.8) years. Unadjusted cumulative HF incidence curves for diabetic and non-diabetic individuals in the study sample 1 over a follow-up time of up to 29.0 years are presented in Fig. 3. The hazard ratio (HR) for HF among diabetic individuals was 2.70 (95% confidence interval [CI], 2.49 – 2.93) when compared to non-diabetic participants.

The associations of each risk factor with incident HF among diabetic and non-diabetic individuals are presented in Fig. 4 (separate models for each risk factor) and Fig. 5 (all risk factors included in the same model). In both analyses, we observed that conventional risk factors (male sex, BMI, smoking, prevalent MI, and prevalent AF) were more strongly related to HF in both diabetic and non-diabetic individuals than the circulating biomarkers, except for nT-proBNP which was associated with HF in both groups (HR 1.26 [CI 1.19 – 1.34] for diabetic and 1.43 [1.39 – 1.47] for non-diabetic individuals).

When the risk factors were analysed in separate models (Fig. 4), male sex, BMI, smoking, baseline MI, triglycerides, glucose, nT-proBNP, hs-Tnl and hs-CRP were directly related to increased HF risk in both diabetic and non-diabetic individuals. HDL cholesterol and vitamin D were inversely related to the increased risk in both groups. Systolic BP, baseline AF and creatinine reached a statistically significant association with increased HF risk in non-diabetic individuals only whereas insulin levels were significantly associated with HF in diabetic individuals only. Interactions terms between diabetes status and systolic BP, baseline MI, baseline AF, nT-proBNP, and hs-CRP as HF risk factors were statistically significant and these associations tended to be stronger in the non-diabetic individuals. The p-value for the interaction term between glucose and diabetes status was 0.067 and thus trended towards significance. Alcohol use and LDL cholesterol were not related to HF risk in either diabetic or non-diabetic individuals in this study.

In the joint analysis with all risk factors included in the same model (Fig. 5), BMI, smoking, baseline history of MI, low HDL cholesterol, triglycerides, nT-proBNP, and low vitamin D were associated with increased HF risk in both diabetic and non-diabetic individuals. Systolic BP, baseline AF, hs-Tnl, and hs-CRP were significantly linked to increased risk of HF in only non-diabetic individuals whereas glucose levels were significantly associated only in diabetic individuals. We observed a significant interaction between diabetes status and systolic BP for HF risk suggesting a stronger association in diabetic than in non-diabetic individuals. Alcohol use, LDL-cholesterol, insulin, and creatinine were not related to HF risk in either diabetic or non-diabetic individuals. A correlation matrix for all risk factors used in these analyses is reported in Additional file 1: Table S3. In sex-specific analyses, low alcohol intake was related to low risk of HF in women with diabetes (women: HR 0.64 [95 CI, 0.43–0.96]; men: HR 0.96 [95 CI, 0.80–1.14]). Heavy smoking was related to HF in both men and women with diabetes, but this association was particularly strong in women with diabetes (women: HR 3.96 [95 CI, 2.56–6.14]; men: HR 1.68 [95 CI, 1.21–2.34]). For biomarkers, the associations with HF were mainly similar in men and women, with the exception of nT-proBNP (women: HR 1.19 [95 CI, 1.08–1.31]; men: HR 1.31 [95 CI, 1.20–1.42]).

To further elucidate the effect of risk factors and the role of diabetes on HF incidence, we performed a mediation analysis with selected risk factors included as mediators of diabetes on the onset of HF in the sample with biomarker data (Fig. 6). The effect of diabetes status on HF risk was only partially explained by the mediators’
Table 1  Characteristics of the study samples

|                     | Sample 1 (whole sample: DAN-MONICA, FINRISK, Moli-sani, SHHEC, Northern Sweden MONICA) | Sample 2 (sample with biomarker data available: FINRISK, Moli-sani, SHHEC, Northern Sweden MONICA) |
|---------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
|                     | Overall | Diabetes | No diabetes | Missing, n (%) | Overall | Diabetes | No diabetes | Missing, n (%) |
| Demographics        |         |          |             |                |         |          |             |                |
| n                   | 94,011  | 3,834    | 90,177      | 55,271 (100)   | 52,799  | 10,370   | 386         | 9,984 (11.1)   |
| Cohort              |         |          |             |                |         |          |             |                |
| DAN-MONICA          | 7,526   | 178      | 7,348       | 7,852 (14.2)   | 14,190  | 239      | 13,951      | 13,951 (26.4)  |
| FINRISK             | 36,907  | 1,526    | 35,381      | 397 (16.1)     | 23,198  | 7,455    | 19,743      | 19,743 (41.2)  |
| Moli-sani           | 23,249  | 1,468    | 21,781      | 21,733 (41.2)  | 15,683  | 21,733   | 4,950       | 4,950 (26.4)   |
| SHHEC               | 10,370  | 386      | 9,984       | 52,799 (100)   | 10,370  | 386      | 9,984       | 9,984 (11.1)   |
| Northern Sweden MONICA |      |          |             |                |         |          |             |                |
| Women               | 48,320  | 1,771    | 46,549      | 28,307 (51.2)  | 27,241  | 161      | 15,665      | 15,665 (29.7)  |
| Age, years          | 48.65   | 57.65    | 48.27       | 51.08 (12.2)   | 50.64   | 60.45    | 50.64       | 50.64 (12.1)   |
| Medication          |         |          |             |                |         |          |             |                |
| Antihypertensive treatment |       |          |             |                |         |          |             |                |
| Alcohol use, g/d    | 10.82   | 10.60    | 10.83       | 2,343 (2.5)    | 12.13   | 12.41    | 12.12       | 12.12 (2.5)    |
| BMI, kg/m²          | 26.17   | 29.16    | 26.05       | 806 (0.9)      | 26.61   | 29.56    | 26.47       | 26.47 (2.5)    |
| Smokers             | 29,914  | 862      | 29,052      | 161 (0.2)      | 16,140  | 475      | 15,665      | 15,665 (29.7)  |
| Systolic BP, mmHg   | 135.23  | 145.80   | 134.79      | 289 (0.3)      | 135.66  | 147.42   | 135.11      | 135.11 (29.7)  |
| Baseline MI         | 2,194   | 303      | 1,891       | 428 (0.3)      | 2,465   | 479      | 1,986       | 1,986 (29.8)   |
| Baseline AF         | 560     | 51       | 501         | 423 (0.3)      | 481     | 418      | 418         | 418 (29.8)     |
| Biomarkers          |         |          |             |                |         |          |             |                |
| HDL, mmol/l         | 1.4 (1.2 − 1.7) | 1.3 (1.1 − 1.5) | 1.4 (1.2 − 1.7) | 1.4 (1.2 − 1.7) | 1.4 (1.2 − 1.7) | 1.4 (1.2 − 1.7) | 1.4 (1.2 − 1.7) | 1.4 (1.2 − 1.7) |
| LDL, mmol/l         | 3.0 (2.4 − 3.8) | 2.9 (2.3 − 3.5) | 3.0 (2.4 − 3.8) | 3.0 (2.4 − 3.8) | 3.0 (2.4 − 3.8) | 3.0 (2.4 − 3.8) | 3.0 (2.4 − 3.8) | 3.0 (2.4 − 3.8) |
| Triglycerides, mmol/l | 1.2 (0.9 − 1.7) | 1.4 (1.0 − 1.9) | 1.2 (0.9 − 1.7) | 1.2 (0.9 − 1.7) | 1.2 (0.9 − 1.7) | 1.2 (0.9 − 1.7) | 1.2 (0.9 − 1.7) | 1.2 (0.9 − 1.7) |
| Insulin, pmol/l     | 66 (4.5 − 10.0) | 96 (6.2 − 15.4) | 65 (4.4 − 9.8) | 1894 (3.4)    | 65 (4.4 − 9.8) | 1894 (3.4)    | 65 (4.4 − 9.8) | 1894 (3.4)    |
| Glucose, mmol/l     | 4.9 (4.5 − 5.5) | 7.3 (5.8 − 9.5) | 4.9 (4.5 − 5.4) | 3,466 (6.2)   | 4.9 (4.5 − 5.4) | 3,466 (6.2)   | 4.9 (4.5 − 5.4) | 3,466 (6.2)   |
| Creatinine, μmol/l  | 70.7 (61.9 − 79.6) | 72.5 (63.6 − 85.7) | 70.7 (61.9 − 79.6) | 1120 (2.0)   | 70.7 (61.9 − 79.6) | 1120 (2.0)   | 70.7 (61.9 − 79.6) | 1120 (2.0)   |
| hs-CRP, mg/l        | 1.4 (0.6 − 2.9) | 2.0 (0.9 − 4.3) | 1.3 (0.6 − 2.8) | 1109 (2.0)    | 1.4 (0.6 − 2.9) | 2.0 (0.9 − 4.3) | 1.3 (0.6 − 2.8) | 1109 (2.0)    |
| nT-proBNP, pg/ml    | 48.3 (25.5 − 90.2) | 67.1 (32.5 − 143.3) | 47.7 (25.3 − 88.1) | 6678 (12.1)    | 48.3 (25.5 − 90.2) | 67.1 (32.5 − 143.3) | 47.7 (25.3 − 88.1) | 6678 (12.1)    |
| hs-TnI, μg/l        | 2.5 (1.4 − 4.3) | 3.2 (2.0 − 5.5) | 2.1 (1.4 − 2.6) | 2634 (4.8)    | 2.5 (1.4 − 4.3) | 3.2 (2.0 − 5.5) | 2.1 (1.4 − 2.6) | 2634 (4.8)    |
| Vitamin D, ng/ml    | 16.2 (11.5 − 22.4) | 15.3 (11.0 − 20.7) | 16.2 (11.5 − 22.4) | 2543 (4.6)    | 16.2 (11.5 − 22.4) | 15.3 (11.0 − 20.7) | 16.2 (11.5 − 22.4) | 2543 (4.6)    |

Data presented as n (% of either overall, diabetic, or non-diabetic population) for categorical and as mean (standard deviation) for continuous variables regarding demographics, diabetes treatment and risk factors, and as median (Q1-Q3) before transformations (square root for HDL, LDL and triglycerides, cube root for others), winsorizing and imputations for biomarkers. Missing data information is presented as n (% of overall) missing for demographics, risk factors and biomarkers, n (% of individuals with diabetes) for diabetes treatment, and for biomarkers also as number imputed. Values for continuous variables are from regular ANOVA with equal variance assumption and for categorical variables from chi-squared tests with continuity correction. p values for all values < 0.001 except for Alcohol use (p = 0.45 in Sample 1 and = 0.484 in Sample 2).

NA not available, MONICA Multinational Monitoring of trends and determinants in Cardiovascular disease, SHHEC Scottish Heart Health Extended Cohort, MI myocardial infarction, AF atrial fibrillation, CHD coronary heart disease, BP blood pressure, HF heart failure, CRP C-reactive protein; nT-proBNP n-terminal atrial natriuretic peptide, type B, hs high sensitivity assay, TnI troponin I, HDL HDL cholesterol, LDL LDL cholesterol
effects (relative effect of all mediators was 56.9% [95% CI 47.7–66.1%] of the whole effect) and a considerable direct effect of diabetes (relative effect 43.1%; 95% CI 33.9–52.3%) was observed. The strongest mediator effects were seen with those represented by BMI (relative effect 13.2%; 95% CI, 10.3–16.2%), glucose (12.0%, 95% CI, 4.2–19.9%), and nT-proBNP (8.4%, 95% CI, -0.07–14.1%). Weak, but statistically significant mediation effects were also observed for the effects represented by systolic BP, HDL cholesterol, triglycerides, hs-TnI, hs-CRP, vitamin D and baseline histories of MI and AF. The effects of insulin and creatinine were selected as covariates by the algorithm (in addition to sex and stratified cohort, decided in advance).

Discussion

In this study, our goal was to elucidate the key correlates and mediators of HF in diabetic individuals. This study confirms the strong association between diabetes and incident HF. Conventional cardiovascular disease risk factors, such as male sex, smoking, BMI, baseline MI, and baseline AF were the strongest correlates of incident HF in the Cox models. In addition, biomarkers for volume overload/cardiac strain (represented by nT-proBNP), myocardial injury (hs-TnI), and inflammation (hs-CRP) were also associated with incident HF. In general, all these associations were equally strong in non-diabetic and in diabetic individuals. However, the strongest indirect mediators of diabetes on incident HF were the effects represented by BMI, hyperglycemia, and volume overload/cardiac strain (the effect represented by nT-proBNP), and with a considerable direct effect of prevalent diabetes status itself as the biggest single driver of HF.

We expected to observe the strongest associations between traditional cardiovascular disease risk factors (such as sex, smoking, BMI, and prior cardiovascular disease) and incident HF in the Cox models. However, these factors were not in general more strongly related to HF in diabetic than in non-diabetic individuals nor were their effects strong mediators of diabetes on HF risk, with the notable exception for the effect represented by BMI. However, even though this relative risk per unit is similar, diabetic patients are likely to have higher BMI and BP levels, which lead to higher absolute risk of HF. Also, the majority of diabetic patients in our study received antihypertensive medication which may confound the association between BP and HF. Furthermore, smoking was one of the stronger risk factors for HF both in diabetic and non-diabetic individuals, especially in women. This observation is in accordance with a previous meta-analysis and it emphasizes the importance of smoking cessation in HF prevention [22]. The lack of association of HF with alcohol use is also in agreement with other studies [23]. Heavy drinkers, however, most likely do not take part in health studies adding a major confounding effect to studies researching associations of heavy drinking. These conventional cardiovascular disease risk factors do not, however, explain the greater than expected HF risk in diabetic patients [1].

The relation of hyperglycemia and HF among diabetic and non-diabetic populations has been assessed
Fig. 4  Association between risk factors and incident heart failure in diabetic and non-diabetic individuals with each risk factor analyzed in an independent model while adjusting for classical risk factors of heart failure. Models are adjusted for sex, alcohol consumption, systolic blood pressure, BMI, baseline myocardial infarction, baseline atrial fibrillation and stratified by cohort. Total number of participants in analyses is 55,271. A total of 319 (12.9%) and 2175 (4.1%) cases of incident heart failure were observed in 2472 and 52,799 individuals with and without diabetes, respectively. HR hazard ratio, CI confidence interval, HF heart failure, BP blood pressure, MI myocardial infarction, CHD coronary heart disease, AF atrial fibrillation, CRP C-reactive protein, nT-proBNP n-terminal atrial natriuretic peptide, type B, hs high sensitivity assay, TnI troponin I
in various studies during the past two decades. The meta-analysis by Aune et al. concluded that the degree of hyperglycemia, even in prediabetic levels, is linearly associated with HF risk [2]. In addition, an improvement in glycemic control was shown to improve systolic and diastolic function in echocardiography in a study...
of 105 diabetes patients with poor glycemic control and no clinical HF [24]. Elevated levels of glucose have also been shown to increase the risk of diabetic cardiomyopathy [7]. In our study, increasing blood glucose levels were significantly associated with incident HF and this association trended towards being stronger in diabetic individuals (p = 0.067). Furthermore, the biggest mediation effect in our study was the direct effect seen with diabetes itself, and it together with the indirect mediation effect represented by glucose was driving 55.1% of the relative share of prevalent diabetes status's effect on incident HF. There are several underlying mechanisms between hyperglycemia and HF risk. Foremost, hyperglycemia leads to increases in advanced glycated end-products in the heart muscle [7]. Hyperinsulinemia promotes cardiac hypertrophy even in healthy individuals and is a crucial part of the development of diabetic cardiomyopathy regardless of glucose levels [25]. Hyperinsulinemia also increases circulating triglycerides levels by activating lipolysis and by increasing the uptake of lipids in cardiomyocytes, resulting in lipotoxicity [26]. However, insulin did not pass mediation tests in our study – meaning it did not associate with both the predictor and outcome variables when other variables were controlled for. The physiological effect of insulin counteracts the deteriorating effect of hyperglycemia on cardiovascular outcomes which could explain why it failed the mediator tests. Furthermore, the heterogeneity of the diabetic population and insulin use might also be other reasons for our findings. The closer examination of the effects of hyperinsulinism on cardiac outcomes would require targeted analyses with type 2 diabetic individuals with endogenous hyperinsulinism. As glucose is also an osmotically active molecule, hyperglycemia leads to intravascular volume overload adding strain to the heart and activates the natriuretic peptide system. These mechanisms increase cardiac stress in a synergistic manner and are even more pronounced in obesity, which itself is also linked to hypervolemia [8].

The natriuretic peptide system acts in a wide spectrum of cardiovascular homeostatic mechanisms, and elevated levels are seen as a consequence in many diseases ranging from hypertension to renal failure [27]. Elevated levels of natriuretic peptides have been demonstrated to predict the onset of HF in asymptomatic individuals, diabetic and non-diabetic, in several studies [28–30]. These prior findings are supported by the indirect mediation effects seen with those represented by glucose and nT-proBNP in our study. Interestingly, natriuretic peptide levels correlate linearly with insulin sensitivity and are often diminished in diabetes and obesity, possibly due to faster clearance [31]. However, in addition to cardiac stretching/hypervolemia, natriuretic peptide levels are also known to increase in the same manner in these individuals in cardiac hypoxia, inflammation, and
observed a limited negative association and an indirect mediation effect between that represented by vitamin D and HF risk in our study. Vitamin D has a broad range of targets in the body and its deficiency has been described as associated with low-level inflammation, atherosclerosis and insulin resistance [10]. In a study of 12,215 participants of the Atherosclerosis Risk in Communities study, vitamin D deficiency was associated with two-fold HF risk in white, but not in black individuals [42]. However, in a recent meta-analysis on the effects of vitamin D on inflammatory markers in HF, Rodriguez et al. concluded that while vitamin D might have a role in the development of HF, evidence on the effect of vitamin D supplementation on clinical outcomes is lacking [43].

As the follow-up of our study extended across several decades, this study is the longest biomarker study in its size to address the relationship of diabetes and HF. However, it has some limitations that need to be considered. All the measurements were made at baseline, and we do not have information on risk factor and biomarker changes over time. Information on diabetes type at baseline and echocardiography data for assessing HF subtype and severity is also missing. In addition, as with all observational studies, a possibility of residual confounding remains due to variation in physical activity, diet, stress, and other factors that may not have been taken into account. Furthermore, our population-based pooled cohorts have substantial heterogeneity which on the other hand can also be considered as a strength of our study since our results can be regarded as pan-European and generalizable to the population of the continent at large. Nevertheless, the study population is dominantly white, and these results may not be generalizable to other ethnic groups. In addition, the exact diagnosis of HF varied by cohort. However, most of the studies relied on data derived from validated national healthcare registers [44–46].

**Conclusions**

Our study adds weight to prior findings on diabetes being a strong predictor of HF in itself, and now backed also by a strong direct mediating effect demonstrated in our study. Conventional cardiovascular risk factors are strongly related to incident HF, but these associations are not in general stronger in diabetic compared to non-diabetic individuals. Our findings suggest that apart from the major direct mediating effect of diabetes, the main indirect mediators of HF risk conveyed by diabetes are the effects represented by obesity, hyperglycemia, and cardiac strain/volume overload. In light of our results and previous evidence, more aggressive weight management, glucose control, and cardiac screening are crucial in the primary prevention of HF in high-risk diabetic patients.

HF pathogenesis in diabetes is driven to an extent by obesity, metabolic syndrome, and the related low-grade inflammation [35]. In this study, BMI was a major HF predictor and the indirect effect represented by it the most significant indirect mediator of the effect of diabetes on HF risk. In addition to BMI, the effect represented by hs-CRP was also a significant mediator of HF risk in diabetes. Obesity and subclinical inflammation have adverse effects on cardiac hemodynamics, structure, function and conduction that predispose to HF [36]. An extensive study of 83,021 type 2 diabetes patients without HF concluded that the risk of HF raises consistently and strongly with BMI and this elevation is 2–3 fold of what is observed in the non-diabetic population [37]. In the StrongHeart study, elevated CRP levels also predicted HF risk in individuals with diabetes or metabolic syndrome [38]. These studies highlight the importance of weight loss in the primary prevention of HF in overweight diabetic individuals. However, further research is needed to establish the links between obesity-related inflammatory biomarkers and HF in diabetes.

LDL cholesterol was not associated with HF, nor did it represent an indirect mediation effect of diabetes on HF in our study. However, as diabetic individuals are more likely to receive efficient cholesterol lowering treatment this might confound any potential links between cholesterol levels and HF risk. In a prior meta-analysis of 132,538 individuals in 17 trials concluded that LDL-lowering statin therapy had a protective role against new onset HF, regardless of whether a preceding MI had occurred [39]. In the Framingham Heart Study, increased HDL cholesterol concentration was associated with reduced HF risk and similar results were observed among diabetic participants of the Multiethnic Study of Atherosclerosis [40, 41]. As prior cardiovascular disease was strongly related to incident HF in our study, it appears that dyslipidemia-driven coronary atherosclerosis is still a major factor in the development of HF in diabetics, but not a major indirect mediator of diabetes’ effect on HF.
There is unmet potential in the use of cardiac biomarkers for HF prediction in diabetes, too, but more evidence is needed on how these markers could be used more effectively in clinical decision-making.

Abbreviations
HF: Heart failure; DM: Diabetes mellitus; MORGAM: MOnica Risk, Genetics, Archiving and Monograph; WHO: World Health Organization; MONICA: Multinational MONItoring of trends and determinants in Cardiovascular disease; SHHEC: Scottish Heart Health Extended Cohort; ICD: International Classification of Diseases, CRP: C-reactive protein; HDL: High Density Lipoprotein; LDL: Low Density Lipoprotein; N-terminal atrial natriuretic peptide; type B; Tnl: Troponin I; hs: High sensitivity assay; BP: Blood pressure; BMI: Body mass index; Mi: Myocardial infarction; AF: Atrial fibrillation; SD: Standard deviation; HR: Hazard ratio; CI: Confidence interval; NA: Not available; KELA: The Social Insurance Institution of Finland.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933‑021‑01378‑4.

Additional file 1: Table S1. a Sources of HF and diabetes diagnoses. Diabetes includes all subtypes. b Detailed definitions for HF and diabetes diagnoses at baseline and for HF also during follow‑up and the respective ICD codes used. Diabetes includes all subtypes. Table S2. Risk table for Figure 3. Table S3. Correlation matrix for all biomarkers and covariates used in analyses.

Acknowledgements
None.

Authors’ contributions
MV conceptualized the research plan and setting, researched the data, wrote the statistical code, wrote the manuscript, contributed to the interpretation and critically revised the manuscript. JR provided statistical counseling, researched the data, wrote the statistical code, contributed to the interpretation and critically revised the manuscript. TN conceptualized the research plan and setting, supervised the project, provided counseling, contributed to the interpretation and critically revised the manuscript. KK contributed to the interpretation and critically revised/edited the manuscript. SSg to the acquisition of data, supervised the project, provided counseling, interpretation and critically reviewed/edited the manuscript. JR provided statistical counseling, the statistical code, wrote the manuscript, contributed to the interpretation and critically revised the manuscript. MV conceptualized the research plan and setting, researched the data, wrote the manuscript, contributed to the interpretation and critically revised the manuscript. The final manuscript was approved by all authors.

Funding
This work was supported by the Juho Vainio Foundation, State research aid of Finland and Turku University Foundation (M.V.), the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation (T.N.), and Academy of Finland, Grant no. 321351 (T.N.). V.S. was supported by the Finnish Foundation for Cardiovascular Research. The MORGAM Project has received funding from EU projects MORGAM (Biomed, BMH4‑CT98‑3183), GenomEUtwin (FP5, QLG2‑CT‑2002‑01254), ENGAGE (FP7, HEALTH‑F4‑2007–201413), CHANCES (FP7, HEALTH‑F3‑2010‑242444), BiomarCaRE (FP7, HEALTH‑F2‑2011‑278913), euCanSHare (Horizon 2020, No. 825903) and AFFECT‑EU (Horizon 2020, No. 847770); and Medical Research Council, London (GG061463, No. 80983; Biomarkers in the MORGAM Populations). This has supported central coordination, workshops and part of the activities of the MORGAM Data Centre, the MORGAM Laboratories and the MORGAM Participating Centres. The SHHEC study was funded by the Scottish Health Department Chief Scientist Organization, the British Heart Foundation and the FP Fleming Trust. The Danish MONICA studies were funded by the Danish National Medical Research Council, Copenhagen County, and the Danish Heart Foundation. The Northern Sweden MONICA study was founded by the county councils in Norr‑and Västerbotten and by Umeå University. The FINRISK Study core data collection was funded by the Finnish Institute for Health and Welfare. The enrolment phase of the Moli‑sani study was supported by research grants from Pfizer Foundation (Rome, Italy), the Italian Ministry of University and Research (MIUR, Rome, Italy)–Programma Triennale di Ricerca, Decreto n. 1588 and Instrumentation Laboratory (Milan, Italy). The follow‑up phase of the Moli‑sani Study (assessment of incident cases) was partially supported by the Italian Ministry of Health (PI GdG, CoPI SC; grant n. RF‑2018‑12367074).

Availability of data and materials
The data are not available in a public repository. Access to the data is restricted by the ethical approvals and the legislation of the European Union and the countries of each study. Approval by the Principal Investigator of each cohort study and the MORGAM BiomarCaRE Steering Group will be required for release of the data. The MORGAM Manual gives more information on access to the data [47].

Declarations
Ethics approval and consent to participate
The included studies have been approved by local ethic committees as follows: MORGAM FINRISK: 1980s: no ethics approval required for observational studies (but current laws allow the use of these data for public health research), 1990s: Ethics committee of the National Public Health Institute (KTL), 2002: Ethics Committee of Epidemiology and Public Health in Hospital District of Helsinki and Uusimaa. MORGAM DAN‑MONICA: Ethics Committee of the Capital Region (formerly Copenhagen County), Denmark. MORGAM Northern Sweden: Research Ethics Committee of Umeå University. MORGAM Moli‑sani: Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia “Agostino Gemelli”, Rome. MORGAM SHHEC: Ethical approval was received from all relevant medical research ethics committees covering the individual populations involved.

Consent for publication
Not applicable.

Competing interests
VS has received honoraria from Novo‑Nordisk and Sanofi for consulting. He also has ongoing research collaboration with Bayer Ltd (all outside this work). SSg has received consultation and speaker’s honoraria from Actelion (outside this work). DW has received honoraria from Abiomed, AstraZeneca, Bayer and Novartis. All other authors declared no competing of interest.

Author details
1Division of Medicine, University of Turku and Turku University Hospital, Kiantymyllynkatu 2, 20521 Turku, Finland. 2Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), Helsinki, Finland. 3Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. 4Cardiovascular Epidemiology Unit, Institute of Cardiovascular Research, University of Dundee, Dundee, UK. 5University Heart Center Hamburg, Hamburg, Germany. 6Catalan Department of Health, Barcelona, Spain. 7Center for Clinical Research and Prevention, Bixelberg and Frederiksberg Hospital, Copenhagen, Denmark. 8Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 9Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy. 10Research Center in Epidemiology and Preventive Medicine, Department of Medicine and Surgery, University of Insibria, Varese, Italy.

Received: 8 June 2021 Accepted: 4 September 2021
Published online: 28 September 2021

References
1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.
2. Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, et al. Diabetes mellitus, blood glucose and the risk of heart failure: a
systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2018;28(1):1081–91.

3. Echouffo-Tcheugui JB, Xu H, DeVore AD, Schulte PJ, Butler J, Yancy CW, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9–20.

4. Sattar N, McGuire DK. Pathways to cardiorenal complications in type 2 diabetes mellitus: a need to rethink. Circulation. 2018;138(1):7–9.

5. Castagno D, Baird‑Gunning J, Jhund PS, Biondi‑Zoccai G, MacDonald MR, Petrie MC, et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta‑analysis. Am Heart J. 2011;162(5):938–948.e2.

6. Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, et al. Heart failure and diabetes: Metabolic alterations and therapeutic interventions: a state-of-The‑Art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39(48):4243–54.

7. Jia G, Whaley‑Connell A, Sowers J. Diabetic cardiomyopathy: a hyper‑glycaemia‑and insulin‑resistance‑induced disease. Diabetologia. 2018;61(1):21–8.

8. Braunwald E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog Cardiovasc Dis. 2019;62(4):298–302.

9. Wang TJ, Wells QS. Vitamin D deficiency and heart failure risk. Not so black and white? JACC Heart Fail. 2015;3(3):357–9.

10. Garbossa SG, Foll F. Vitamin D, sub‑inflammation and insulin resistance. A potential on a window for the interaction between bone and glucose metabolism. Rev Endocor Metab Disord. 2017;18(2):243–58.

11. Evans A, Saloma V, Kulathinal S, Asplund H, Ferrari M, et al. MORGAM (an international pooling of cardiovascular cohorts). Int J Epidemiol. 2005;34(1):21–7.

12. Kulathinal S, Niemela M, Niiranen T, Saarela O, Palosaari T, Tapanainen H, et al. Description of MORGAM Cohorts [Internet]. 2005. https://www.thl.fi/publications/morgam/cohorts/full/contents.htm. Accessed 6 Jun 2021.

13. WHO. International Classification of Diseases 10th Revision [Internet]. 2018. http://apps.who.int/classifications/icd10/browse/2016/en. Accessed 9 Sep 2019.

14. Tunstall‑Pedoe H, Kuulasmaa K, Tolonen H, Davidson M, Mendis S, Project WHO. MONICA monograph and multimedia sourcebook : world’s largest study of heart disease, stroke, risk factors, and population trends 1979–2002/edited by Hugh Tunstall‑Pedoe.; prepared by Hugh Tunstall‑Pedoe. ... [et al] with 64 other contributors for the WH. Geneva: World Health Organization; 2003.

15. Korn EL, Graubard BI, Midthune D. Time‑to‑event analysis of longitudinal follow‑up of a survey: choice of the time‑scale. Am J Epidemiol. 1997;145(1):72–80.

16. Colainge J, Hsu W-L, Abbott RD, Ohishi W, Grant EJ, Fujiwara S, et al. Proportional hazards regression in epidemiologic follow‑up studies: an intuitive consideration of primary time scale. Epidemiology. 1997;145(1):72–80.

17. Thiébaut ACM, Bénichou J. Choice of time‑scale in Cox's model analysis of epidemiologic cohort data: a simulation study. Stat Med. 2004;23(24):3803–20.

18. Yu Q, Wu X, Li B, Schnbrn RA. Multiple mediation analysis with survival outcomes: With an application to explore racial disparity in breast cancer survival. Stat Med. 2019;38(3):398–412.

19. Team RC. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020.

20. Yu Q, Li B. mma: An R Package for Mediation Analysis with Multiple Mediators. J Open Res Softw. 2017;5(1):11.

21. van Buuren S, Groothuis‑Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67.

22. Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of heart failure: a systematic review and meta‑analysis of prospective studies. Eur J Prev Cardiol. 2019;26(3):279–88.

23. Larsson SC, Wallin A, Wolk A. Alcohol consumption and risk of heart failure: meta‑analysis of 13 prospective studies. Curr Nutr. 2018;37(4):1347–51.

24. Leung M, Wong VW, Hudson M, Leung DY. Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus. Circ Cardiovasc Imaging. 2016;9(3):1–9.

25. Riehle C, Abel ED. Insulin Signaling and Heart Failure. Circ Res. 2016;118(7):1511–69.

26. Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab. 2012;15(6):805–12.

27. Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698–717.

28. Scircia BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im KA, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: A secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(9):989–98.

29. Ng I, Burk W, Bertoni A, Budoff MJ, Delfiippi C, Lombardo D, et al. N-terminal Pro B-type Natriuretic Peptide and High‑sensitivity Cardiac Troponin as Markers for Heart Failure and Cardiovascular Disease Risks According to Glucose Status (from the Multi‑Ethnic Study of Atherosclerosis (MESA)): Am J Cardiol. 2020;125(8):1194–201.

30. Okhuma T, Jun M, Woodward M, Zoungas S, Cooper ME, Grobbee DE, et al. Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes. The ADVANCE trial. Diabetes Care. 2017;40(9):1203–9.

31. Sanchez OA, Dupertz DA, Bahrami H, Daniels LB, Folsom AR, Lima JA, et al. The associations between metabolic variables and NT‑proBNP are blunted at pathological ranges: The Multi‑Ethnic Study of Atherosclerosis. Metabolism. 2014;63(4):473–83.

32. Bolam H, Morton G, Kalra PR. Drug therapies in chronic heart failure: A focus on reduced ejection fraction. Clin Med J R Coll Physicians London. 2018;18(2):138–45.

33. Lazar S, Rayner B, Lopez Campos G, McGrath K, McClements L. Mechanisms of heart failure with preserved ejection fraction in the presence of diabetes mellitus. Transl Metab Syndr Res. 2020;3:1–5.

34. Iwakura K. Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihypoglycemic treatments. J Echocardiogr. 2019;17(4):177–86.

35. Van Linhout S, Tschöpe C. Inflammation—cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017;14(4):251–65.

36. Ebong IA, Goff DC, Rodriguez CJ, Chen H, Bertoni AG. Mechanisms of heart failure in obesity. Obes Res Clin Pract. 2014;8(6):e540–8.

37. Glogner S, Rosengren A, Olsson M, Gudbjornsdottir S, Svensson AM, Lind M. The association between BMI and hospitalization for heart failure in 83 021 persons with Type 2 diabetes: a population‑based study from the Swedish National Diabetes Registry. Diabet Med. 2014;31(5):586–94.

38. Barac A, Wang H, Shara NM, de Simone G, Carter EA, Umanis JG, et al. Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: The strong heart study. J Clin Hypertens. 2012;14(1):13–9.

39. Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, et al. Effect of statin therapy on heart failure outcomes: a collaborative meta‑analysis of unpublished data from major randomized trials. Eur Heart J. 2015;36(24):1536–46.

40. Velagali RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of lipid concentrations to heart failure incidence. The Framingham Heart Study. Circulation. 2009;120(23):2345–51.

41. Ebong IA, Goff DC, Rodriguez CJ, Chen H, Bertoni AG. Mechanisms of heart failure in obesity. Obes Res Clin Pract. 2014;8(6):e540–8.

42. Lutseny PL, Michos ED, Mislalek JR, Pankow JS, Loehr L, Selvin E, et al. Race and vitamin D binding protein gene polymorphisms modify the association of 25‑hydroxyvitamin D and incident heart failure. The ARC (Atherosclerosis Risk in Communities) Study. JACC Heart Fail. 2015;3(3):374–86.

43. Rodriguez AJ, Moua A, Ebeling PR, Scott D, De Courten B. Effects of Vitamin D supplementation on inflammatory markers in heart failure: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):2–9.

44. Vuori MA, Laukkanen JA, Pietilä A, Havelinisa AS, Kähönén M, Salomaa V, et al. The validity of heart failure diagnoses in the Finnish Hospital Discharge Register. Scand J Public Health. 2019;47:20–8.

45. Deløka J, Hansen SM, Alzuhari KS, Bork CS, Joensen AM. The validity of the diagnosis of heart failure (I50.0–I50.9) in the Danish National Patient Register. Dan Med J. 2018;65(4):2–6.
46. Ingelsson E, Ärnlöv J, Sundström J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7(5):787–91.
47. MORGAM Project. MORGAM Manual. MORGAM Project e-publications [Internet]. 2001–; (1). URN:NBN:fi:five20041529 Available from URL: https://www.thl.fi/publications/morgam/manual/contents.htm

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions